BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36596981)

  • 1. Differential Profile of Primary and Recurrent Ameloblastomas Among Afro-descendants and Non-Afro-descendants-a Systematic Review.
    Patel P; Effiom OA; Akinshipo AO; Akintoye SO
    J Racial Ethn Health Disparities; 2024 Feb; 11(1):92-100. PubMed ID: 36596981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [BRAF V600E expression in ameloblastomas, ameloblastic carcinomas and cysts].
    Pei J; Zhang L; Jia YX; Chen WH
    Shanghai Kou Qiang Yi Xue; 2023 Dec; 32(6):630-634. PubMed ID: 38494972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High frequency of BRAF V600E mutations in ameloblastoma.
    Kurppa KJ; Catón J; Morgan PR; Ristimäki A; Ruhin B; Kellokoski J; Elenius K; Heikinheimo K
    J Pathol; 2014 Apr; 232(5):492-8. PubMed ID: 24374844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does BRAF V600E mutation affect recurrence rate of ameloblastomas? Systematic review and meta-analysis.
    Martins-de-Barros AV; Silva CCG; Gonçalves KKN; de Albuquerque Cavalcanti Almeida R; de Oliveira E Silva ED; da Costa Araújo FA; Robinson L; van Heerden WFP; de Vasconcelos Carvalho M
    J Oral Pathol Med; 2023 Sep; 52(8):701-709. PubMed ID: 37364158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
    Brown NA; Rolland D; McHugh JB; Weigelin HC; Zhao L; Lim MS; Elenitoba-Johnson KS; Betz BL
    Clin Cancer Res; 2014 Nov; 20(21):5517-26. PubMed ID: 24993163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma.
    Mendez LD; Wolsefer NS; Asa SL; Wasman J; Yoest JM; Stojanov IJ
    Mod Pathol; 2022 Nov; 35(11):1570-1577. PubMed ID: 35676332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of BRAF V600E mutation in a group of Thai patients with ameloblastomas.
    Lapthanasupkul P; Laosuk T; Ruangvejvorachai P; Aittiwarapoj A; Kitkumthorn N
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Nov; 132(5):e180-e185. PubMed ID: 32665205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ameloblastoma with mucous cells: A clinicopathological, BRAF mutation, and MAML2 rearrangement study.
    Xia RH; Zhang CY; Sun JJ; Tian Z; Hu YH; Gu T; Wang LZ; Li J
    Oral Dis; 2020 May; 26(4):805-814. PubMed ID: 31954088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Mutational Profile of Unicystic Ameloblastoma.
    Heikinheimo K; Huhtala JM; Thiel A; Kurppa KJ; Heikinheimo H; Kovac M; Kragelund C; Warfvinge G; Dawson H; Elenius K; Ristimäki A; Baumhoer D; Morgan PR
    J Dent Res; 2019 Jan; 98(1):54-60. PubMed ID: 30216733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAFV600E mutation in the diagnosis of unicystic ameloblastoma.
    Pereira NB; Pereira KM; Coura BP; Diniz MG; de Castro WH; Gomes CC; Gomez RS
    J Oral Pathol Med; 2016 Nov; 45(10):780-785. PubMed ID: 27084044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment options for advanced ameloblastoma in the era of precision medicine: A brief review.
    Oh KY
    Oral Oncol; 2023 Nov; 146():106585. PubMed ID: 37816291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of molecular-targeted chemotherapy in ameloblastomas: A systematic review.
    Yoithapprabhunath TR; Srichinthu KK; Gupta D; Singh D; Pasupuleti S; Nirmal RM
    Indian J Dent Res; 2022; 33(3):323-331. PubMed ID: 36656197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of MDM2 Overexpression in Ameloblastomas with
    Tosios KI; Kalogirou EM; Koutlas IG
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of recurrent SMO and BRAF mutations in ameloblastomas.
    Sweeney RT; McClary AC; Myers BR; Biscocho J; Neahring L; Kwei KA; Qu K; Gong X; Ng T; Jones CD; Varma S; Odegaard JI; Sugiyama T; Koyota S; Rubin BP; Troxell ML; Pelham RJ; Zehnder JL; Beachy PA; Pollack JR; West RB
    Nat Genet; 2014 Jul; 46(7):722-5. PubMed ID: 24859340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA damage response activation and cell cycle dysregulation in infiltrative ameloblastomas: A proposed model for ameloblastoma tumor evolution.
    Diniz MG; Guimarães BVA; Pereira NB; de Menezes GHF; Gomes CC; Gomez RS
    Exp Mol Pathol; 2017 Jun; 102(3):391-395. PubMed ID: 28454892
    [No Abstract]   [Full Text] [Related]  

  • 16. [Research advances in the v-raf murine sarcoma viral oncogene homolog gene mutation in ameloblastoma].
    Yan XC; Sun LS; Dong ZW; You Z; Dong Q
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Jul; 53(7):500-502. PubMed ID: 29996373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ameloblastoma-Clinical, radiological, and therapeutic findings.
    Kreppel M; Zöller J
    Oral Dis; 2018 Mar; 24(1-2):63-66. PubMed ID: 29480593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An immunohistochemical and genetic study of BRAF
    Seki-Soda M; Sano T; Ito K; Yokoo S; Oyama T
    Pathol Int; 2020 Apr; 70(4):224-230. PubMed ID: 31930640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single institution.
    Owosho AA; Ladeji AM; Adebiyi KE; Olajide MA; Okoye ISI; Kehinde T; Nwizu NN; Summersgill KF
    Eur Arch Otorhinolaryngol; 2021 Aug; 278(8):3065-3071. PubMed ID: 33231757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and evaluation of the presence of the BRAF V600E mutation in ameloblastomas in an Indian population.
    Goes CF; Spadigam A; Dhupar A; Carvalho KM; Cota J; Syed S
    Indian J Pathol Microbiol; 2023; 66(2):246-251. PubMed ID: 37077063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.